Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
53%
Adverse Event
41%
Allergic Rhinitis
32%
Allopurinol
41%
Anticoagulant Agent
69%
Antivitamin K
39%
Anxiety Disorder
30%
Apixaban
27%
Asthma
56%
Atrial Fibrillation
41%
Benzbromarone
30%
Bleeding
39%
Case-Control Study
30%
Chemotherapy
32%
Ciclonicate
37%
Cohort Study
63%
Community Pharmacy
47%
Comorbidity
49%
Cyclophosphamide
30%
Dabigatran
31%
Defined Daily Dose
27%
Diffuse Large B Cell Lymphoma
30%
Direct Oral Anticoagulant
41%
Disease
67%
Drug Interaction
41%
Drug-Drug Interaction
44%
Gout
33%
Infection
40%
Leflunomide
82%
Methotrexate
27%
Metoprolol
30%
Mood Disorder
30%
Multiple Myeloma
71%
Myelodysplastic Syndrome
61%
Nadroparin
30%
Non-Steroidal Anti-Inflammatory Drug
43%
Observational Study
72%
Overall Survival
43%
Peripheral Neuropathy
30%
Pharmacokinetics
35%
Pharmacotherapy
74%
Psychotropic Agent
28%
Randomized Controlled Trial
42%
Rheumatoid Arthritis
100%
Rituximab
50%
Rivaroxaban
37%
Symptom
41%
Tolerability
27%
Toxic Injury
41%
Vitamin D
62%
Medicine and Dentistry
Adverse Event
27%
Alloimmunization
20%
Anticoagulant Therapy
15%
Antithrombotic
33%
Asthma
57%
Atrial Fibrillation
30%
Bariatric Surgery
51%
Benralizumab
22%
Bladder Capacity
20%
Bleeding
31%
Case-Control Study
20%
Ciclonicate
24%
Clinical Trial
14%
Cohort Analysis
36%
Colecalciferol
16%
Diffuse Large B-Cell Lymphoma
30%
Disease
42%
Drug Therapy
92%
Drug Use
41%
Electronic Health Record
24%
Eosinophil
16%
Eosinophilic
29%
Frail Elderly
24%
Geriatrician
23%
Health Care Cost
28%
Hypovitaminosis D
15%
Intensive Care Unit
27%
Leflunomide
20%
Low Molecular Weight Heparin
20%
Multiple Myeloma
51%
Myelodysplastic Syndrome
71%
Nadroparin Calcium
20%
Nonsteroid Antiinflammatory Agent
20%
Observational Study
50%
Outpatient
30%
Overall Survival
39%
Peripheral Neuropathy
20%
Placebo
21%
Randomized Controlled Trial
22%
Respiratory Tract Inflammation
30%
Resuscitation
14%
Sepsis
22%
Septic Shock
20%
Severe Asthma
34%
Somatics
35%
Sputum
19%
Thromboprophylaxis
20%
Urinary Catheterization
19%
Vitamin D
51%
Vitamin K Antagonist
30%
Keyphrases
A77 1726
20%
Adverse Drug Reaction
30%
After Surgery
25%
Anxiety Disorders
20%
Atrial Fibrillation
30%
Bariatric Surgery
51%
Benralizumab
22%
Benzbromarone
20%
Clinical Significance
23%
Comorbidity
21%
Critically Ill Patients
20%
Cyclophosphamide
20%
Diffuse Large B-cell Lymphoma (DLBCL)
20%
Direct Oral Anticoagulants
30%
Doxorubicin
20%
Drug Use
38%
Dutch
67%
Hospital Pharmacy
26%
Leflunomide
51%
Low Molecular Weight Heparin
20%
Medication Discrepancies
20%
Medication Use
23%
Minor Bleeding
30%
Mood Disorders
20%
Multiple Myeloma Patients
41%
Myelodysplastic Syndrome
20%
Netherlands
53%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
20%
Non-vitamin K Antagonist Oral Anticoagulants
30%
Older Patients
20%
Oral Vitamin D
20%
Outpatient Department
20%
Overall Survival
19%
P450 2D6
20%
Pediatric
20%
Peripheral Neuropathy
20%
Pharmacotherapy
46%
Pharmacy
19%
Population-based Cohort Study
30%
Randomized Controlled Trial
42%
Reporting Quality
20%
Rheumatoid Arthritis
33%
Risk Factors
24%
Risk Relevance
20%
Rituximab
30%
Serum Concentration
24%
Severe Asthma
34%
Structured Assessment
20%
Structured Medication Review
20%
Vitamin D
33%
